Joseph M. Pierre, MD

Article

Conspiracy theory or delusion? 3 questions to tell them apart

Author:: Joseph M. Pierre, MD

Publish date: September 1, 2021

Many psychiatrists conceptualize mental illnesses, including psychotic disorders, across a continuum where their borders can be ambiguous.

Opinion

Believing in conspiracy theories is not delusional

Author:: Joseph M. Pierre, MD

Publish date: February 5, 2021

Instead of trying to “talk the patient out of” his or her belief, focus on sustaining and strengthening the physician-patient alliance.

Article

Time to retire haloperidol?

Author:: Joseph M. Pierre, MD

Publish date: May 1, 2020

For emergency agitation, evidence suggests newer alternatives may be a better choice.

Article

Cannabidiol (CBD) for schizophrenia: Promise or pipe dream?

Author:: Joseph M. Pierre, MD

Publish date: May 1, 2019

The evidence is mixed, and the benefits are uncertain.

Article

Abuse of psychiatric medications: Not just stimulants and benzodiazepines

Author:: Joseph M. Pierre, MD

Publish date: January 2, 2019

Anticholinergics, antidepressants, antipsychotics, and gabapentinoids may also be subject to misuse or abuse.

Article

Real-world challenges in managing ‘dual diagnosis’ patients

Author:: Joseph M. Pierre, MD

Publish date: September 1, 2018

Diligent assessment and judicious prescribing can help optimize outcomes.

Article

Risks of increasingly potent Cannabis: The joint effects of potency and frequency

Author:: Joseph M. Pierre, MD

Publish date: February 1, 2017

As THC levels rise, the risk of psychosis, cognitive deficits, and structural brain changes increases In the United States, the average potency of ...

Article

Cannabis, synthetic cannabinoids, and psychosis risk: What the evidence says

Author:: Joseph M. Pierre, MD

Publish date: September 1, 2011

Research suggests marijuana may be a ‘component cause’ of psychosis

News

High-dose antipsychotics: Desperation or data-driven?

Author:: Joseph M. Pierre, MD

Publish date: August 1, 2004

For patients on the brink of the neuroleptic threshold, risks of high-dose antipsychotics may outweigh any benefit.